Treatment of experimental autoimmune myasthenia gravis with recombinant human tumor necrosis factor receptor Fc protein. (Q53983532)

23 May 2018

title

Treatment of experimental autoimmune myasthenia gravis with recombinant human tumor necrosis factor receptor Fc protein. (English)

1 reference

23 May 2018

main subject

myasthenia gravis

0 references

author name string

Premkumar Christadoss

series ordinal

1 reference

23 May 2018

Elzbieta Goluszko

series ordinal

1 reference

23 May 2018

publication date

1 January 2002

1 reference

23 May 2018

Journal of Neuroimmunology

published in

1 reference

23 May 2018

volume

122

1 reference

23 May 2018

issue

1-2

1 reference

23 May 2018

page(s)

186-190

1 reference

23 May 2018

Unraveling function in the TNF ligand and receptor families

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900473-8

7 January 2021

T-lymphocyte interferon-gamma receptor binding in patients with myasthenia gravis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900473-8

7 January 2021

Animal models of myasthenia gravis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900473-8

7 January 2021

Inhibition of tumor necrosis factor activity minimizes target organ damage in experimental autoimmune uveoretinitis despite quantitatively normal activated T cell traffic to the retina

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900473-8

7 January 2021

Neutralizing TNF-alpha activity modulates T-cell phenotype and function in experimental autoimmune uveoretinitis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900473-8

7 January 2021

Taming TNF: strategies to restrain this proinflammatory cytokine

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900473-8

7 January 2021

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900473-8

7 January 2021

Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900473-8

7 January 2021

Lymphotoxin-alpha deficiency completely protects C57BL/6 mice from developing clinical experimental autoimmune myasthenia gravis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900473-8

7 January 2021

Tumor necrosis factor receptor p55 and p75 deficiency protects mice from developing experimental autoimmune myasthenia gravis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900473-8

7 January 2021

Polymorphism in tumor necrosis factor genes associated with myasthenia gravis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900473-8

7 January 2021

Tumour necrosis factor-alpha polymorphism and secretion in myasthenia gravis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900473-8

7 January 2021

Immunohistological patterns of non-neoplastic changes in the thymus in Myasthenia gravis.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900473-8

7 January 2021

Interleukin 6 influences germinal center development and antibody production via a contribution of C3 complement component

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900473-8

7 January 2021

29 Production and assay of antibodies to acetylcholine receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900473-8

7 January 2021

Role of lymphotoxin and the type I TNF receptor in the formation of germinal centers

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900473-8

7 January 2021

Lymphotoxin-alpha-deficient and TNF receptor-I-deficient mice define developmental and functional characteristics of germinal centers

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900473-8

7 January 2021

Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)–Fc Fusion Protein

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900473-8

7 January 2021

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900473-8

7 January 2021

Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune re

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900473-8

7 January 2021

Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900473-8

7 January 2021

Experimental autoimmune encephalomyelitis: immunotherapy with anti-tumor necrosis factor antibodies and soluble tumor necrosis factor receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900473-8

7 January 2021

In vivo relationship of tumor necrosis factor-alpha to blood-brain barrier damage in patients with active multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900473-8

7 January 2021

Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900473-8

7 January 2021

Anti-tumor necrosis factor therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900473-8

7 January 2021

Tumor necrosis factor receptor-1 is critically involved in the development of experimental autoimmune myasthenia gravis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900473-8

7 January 2021

10.1016/S0165-5728(01)00473-8

Identifiers

DOI

1 reference

23 May 2018

1 reference

23 May 2018